ReviewOncology research2026
Small Molecule Targeted Therapy for Hepatocellular Carcinoma: From Multikinase Inhibition to Cancer Stem Cell Eradication Strategies.
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, posing a significant global health burden. Multikinase inhibitors (MKIs) such as sorafenib and lenvatinib are standard therapies for advanced HCC, yet most patients eventually develop drug resistance and tumor relapse, largely attributed to the presence of cancer stem cells (CSCs). These cells, which possess self-renewal capacity and intrinsic resistance to conventional treatments, drive tumor heterogeneity and recurrence. This review examines the molecular features of HCC CSCs and their regulatory networks, including Wnt/β-catenin, Phosphoinositide 3-kinase (PI3K)/Akt/Mammalian target of rapamycin (mTOR), and Notch signaling pathways. CSCs drive tyrosine kinase inhibitor (TKI) resistance through mechanisms such as Caveolin 1 (CAV1)-mediated dormancy and the CD133/Myosin heavy chain 9 (MYH9)/β-catenin axis, which sustain survival and proliferation despite targeted therapy. Recent preclinical studies have identified small molecule inhibitors targeting CSC-specific pathways and markers, including C504244, 4-MU, bestatin, OSU-CG5, and CL26, which show promise in eradicating CSC populations. Combination strategies that pair TKIs with these agents demonstrate synergistic effects, particularly when delivered via nanoparticle systems, which enhance drug bioavailability and tumor targeting. However, major barriers to clinical translation include CSC heterogeneity, microenvironmental adaptation, and the lack of reliable biomarkers for patient stratification. The shift from multikinase inhibition to CSC eradication represents a promising paradigm for transforming HCC into a more manageable disease, potentially improving long-term outcomes and reducing relapse rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.